Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board
Golden, Colorado, Nov. 03, 2023 (GLOBE NEWSWIRE) — Theralink Technologies, Inc. (OTC: THER) (“Theralink”), a precision oncology company with its exclusive commercial RPPA (reverse phase protein array) technology that can help predict which FDA-approved drug is effective in each cancer, today announced that their long-standing, strategic partnership with the Inova Schar Cancer Institute (Inova) is beginning to deliver promising results by way of assessing the feasibility and impact of the actionable information provided by the Theralink assay into Inova’s Molecular Tumor Board (MTB)-based treatment decisioning making for cancer patients.
Related news for (THER)
- Theralink announces groundbreaking RPPA study by partner GMU – reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates
- Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4
- Theralink Announces Filing of Form S-4; Merger with IMAC Holdings Expected During Q4 2023
- Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer